<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36383259</PMID><DateCompleted><Year>2023</Year><Month>03</Month><Day>01</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1432-1459</ISSN><JournalIssue CitedMedium="Internet"><Volume>270</Volume><Issue>3</Issue><PubDate><Year>2023</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Journal of neurology</Title><ISOAbbreviation>J Neurol</ISOAbbreviation></Journal><ArticleTitle>Italian version of the Rasch-Built Overall Amyotrophic Lateral Sclerosis Disability Scale (ROADS): validation and longitudinal performance.</ArticleTitle><Pagination><StartPage>1452</StartPage><EndPage>1456</EndPage><MedlinePgn>1452-1456</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00415-022-11483-3</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To validate an Italian version of the Rasch-Built Overall ALS Disability Scale (ROADS) in a broad population of patients and assess its longitudinal performance over time.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">270 ALS patients referring to the Motor Neuron Disease Clinic of the University of Padova and Modena (Italy) accepted to compile the Italian version of the ROADS and results were correlated with the ALSFRSr and ALSAQ-40 scores, FVC values, and creatinine or albumin blood levels. To verify test-retest reliability, patients were asked to fill in a second copy of the scale within 5-7&#xa0;days. Thirty-nine patients compiled a further copy of questionnaire during the follow up visit (after 133&#xa0;days on average) which allowed us a longitudinal assessment of the scale.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We found a good external construct validity between ROADS and either ALSFRS-R (correlation coefficient&#x2009;=&#x2009;0.85) or ALSAQ-40 (correlation coefficient&#x2009;=&#x2009;-&#x2009;0.84). Test-retest reliability was excellent with a concordance-correlation coefficient of 0.93. Yet, we observed a significant correlation between changes over time of the ROADS normalised sum score (-&#x2009;2.18 point loss per month) and those of both the ALSFRS-R (positive correlation; Rho&#x2009;=&#x2009;0.64, p&#x2009;&#x2264;&#x2009;0.0001) or the ALSAQ-40 (negative correlation; Rho&#x2009;=&#x2009;-&#x2009;0.60, p&#x2009;=&#x2009;0.014).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The Italian version of ROADS proved to be a reliable marker to monitor overall disability in ALS patients. Further studies are necessary to assess its longitudinal performance.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fortuna</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, Neuromuscular Center, University of Padova, 35128, Padua, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sabbatini</LastName><ForeName>Daniele</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, University of Padova, Padua, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frigo</LastName><ForeName>Annachiara</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Unit of Biostatistics, Epidemiology and Public Health, Department of Cardiac, Thoracic and Vascular Sciences, University of Padova, Padua, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bello</LastName><ForeName>Luca</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, Neuromuscular Center, University of Padova, 35128, Padua, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Calvi</LastName><ForeName>Francesca</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, Neuromuscular Center, University of Padova, 35128, Padua, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blasi</LastName><ForeName>Lorenzo</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, Neuromuscular Center, University of Padova, 35128, Padua, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gianferrari</LastName><ForeName>Giulia</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Neurology Unit, S. Agostino Estense Hospital, AziendaOspedalieroUniversitaria di Modena, Modena, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martinelli</LastName><ForeName>Ilaria</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Neurology Unit, S. Agostino Estense Hospital, AziendaOspedalieroUniversitaria di Modena, Modena, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Minicuci</LastName><ForeName>Giacomo</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Neuromuscular Center, S. Bortolo Hospital, Vicenza, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pegoraro</LastName><ForeName>Elena</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, Neuromuscular Center, University of Padova, 35128, Padua, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mandrioli</LastName><ForeName>Jessica</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Neuromuscular Center, S. Bortolo Hospital, Vicenza, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sorar&#xf9;</LastName><ForeName>Gianni</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0001-9691-6328</Identifier><AffiliationInfo><Affiliation>Department of Neurosciences, Neuromuscular Center, University of Padova, 35128, Padua, Italy. gianni.soraru@unipd.it.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>11</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>J Neurol</MedlineTA><NlmUniqueID>0423161</NlmUniqueID><ISSNLinking>0340-5354</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>J Neurol. 2023 Feb 22;:</RefSource><PMID Version="1">36811681</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000203" MajorTopicYN="N">Activities of Daily Living</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016472" MajorTopicYN="Y">Motor Neuron Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007558" MajorTopicYN="N" Type="Geographic">Italy</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALS</Keyword><Keyword MajorTopicYN="N">ALSFRS-R</Keyword><Keyword MajorTopicYN="N">Italian</Keyword><Keyword MajorTopicYN="N">ROADS</Keyword><Keyword MajorTopicYN="N">Scale</Keyword><Keyword MajorTopicYN="N">Validation</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>9</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>11</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>11</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>16</Day><Hour>11</Hour><Minute>15</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36383259</ArticleId><ArticleId IdType="pmc">PMC9971085</ArticleId><ArticleId IdType="doi">10.1007/s00415-022-11483-3</ArticleId><ArticleId IdType="pii">10.1007/s00415-022-11483-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Mora JS, Genge A, Chio A, et al. Masitinib as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomized clinical trial. Amyotroph Lateral Scler Frontotemporal Degener. 2020;21(1&#x2013;2):5&#x2013;14. doi: 10.1080/21678421.2019.1632346.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2019.1632346</ArticleId><ArticleId IdType="pubmed">31280619</ArticleId></ArticleIdList></Reference><Reference><Citation>Shibuya K, Misawa S, Kimura H, et al. A single blind randomized controlled clinical trial of mexiletine in amyotrophic lateral sclerosis: efficacy and safety of sodium channel blocker phase II trial. Amyotroph Lateral Scler Frontotemporal Degener. 2015;16(5&#x2013;6):353&#x2013;358. doi: 10.3109/21678421.2015.1038277.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2015.1038277</ArticleId><ArticleId IdType="pubmed">25960085</ArticleId></ArticleIdList></Reference><Reference><Citation>Shefner JM, Liu D, Leitner ML, et al. Quantitative strength testing in ALS clinical trials. Neurology. 2016;87(6):617&#x2013;624. doi: 10.1212/WNL.0000000000002941.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000002941</ArticleId><ArticleId IdType="pmc">PMC4977369</ArticleId><ArticleId IdType="pubmed">27385750</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson CE, Gronseth G, Rosenfeld J, et al. Randomized double-blind study of botulinum toxin type B for sialorrhea in ALS patients. Muscle Nerve. 2009;39(2):137&#x2013;143. doi: 10.1002/mus.21213.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.21213</ArticleId><ArticleId IdType="pubmed">19145653</ArticleId></ArticleIdList></Reference><Reference><Citation>Vanhoutte EK, Hermans MCE, Faber CG, Gorson KC, Merkies ISJ, Thonnard J-L. Rasch-ionale for neurologists. J Peripher Nerv Syst. 2015;20(3):260&#x2013;268. doi: 10.1111/jns.12122.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jns.12122</ArticleId><ArticleId IdType="pubmed">26115370</ArticleId></ArticleIdList></Reference><Reference><Citation>Franchignoni F, Mandrioli J, Giordano A, Ferro S. A further Rasch study confirms that ALSFRS-R does not conform to fundamental measurement requirements. Amyotroph Lateral Scler Frontotemporal Degener. 2015;16(5&#x2013;6):331&#x2013;337. doi: 10.3109/21678421.2015.1026829.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2015.1026829</ArticleId><ArticleId IdType="pubmed">25916346</ArticleId></ArticleIdList></Reference><Reference><Citation>Franchignoni F, Mora G, Giordano A, Volanti P, Chi&#xf2; A. Evidence of multidimensionality in the ALSFRS-R Scale: a critical appraisal on its measurement properties using Rasch analysis. J Neurol Neurosurg Psychiatry. 2013;84(12):1340&#x2013;1345. doi: 10.1136/jnnp-2012-304701.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2012-304701</ArticleId><ArticleId IdType="pubmed">23516308</ArticleId></ArticleIdList></Reference><Reference><Citation>Fournier CN, Bedlack R, Quinn C, et al. Development and validation of the rasch-built overall amyotrophic lateral sclerosis disability scale (ROADS) JAMA Neurol. 2020;77(4):480&#x2013;488. doi: 10.1001/jamaneurol.2019.4490.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2019.4490</ArticleId><ArticleId IdType="pmc">PMC6990811</ArticleId><ArticleId IdType="pubmed">31886839</ArticleId></ArticleIdList></Reference><Reference><Citation>Manera U, Solero L, Fournier CN, et al. Validation of the Italian version of the Rasch-Built Overall Amyotrophic Lateral Sclerosis Disability Scale (ROADS) administered to patients and their caregivers. Amyotroph Lateral Scler Frontotemporal Degener. 2021 doi: 10.1080/21678421.2021.2013892.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2021.2013892</ArticleId><ArticleId IdType="pubmed">34894916</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR, Miller RG, Swash M, Munsat TL. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph lateral Scler other Mot neuron Disord Off Publ World Fed Neurol Res Gr Mot Neuron Dis. 2000;1(5):293&#x2013;299. doi: 10.1080/146608200300079536.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/146608200300079536</ArticleId><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmieri A, Sorar&#xf9; G, Lombardi L, et al. Quality of life and motor impairment in ALS: Italian validation of ALSAQ. Neurol Res. 2010;32(1):32&#x2013;40. doi: 10.1179/174313209X385734.</Citation><ArticleIdList><ArticleId IdType="doi">10.1179/174313209X385734</ArticleId><ArticleId IdType="pubmed">20092693</ArticleId></ArticleIdList></Reference><Reference><Citation>Czaplinski A, Yen AA, Appel SH. Forced vital capacity (FVC) as an indicator of survival and disease progression in an ALS clinic population. J Neurol Neurosurg Psychiatry. 2006;77(3):390&#x2013;392. doi: 10.1136/jnnp.2005.072660.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2005.072660</ArticleId><ArticleId IdType="pmc">PMC2077717</ArticleId><ArticleId IdType="pubmed">16484652</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A, Calvo A, Bovio G, et al. Amyotrophic lateral sclerosis outcome measures and the role of albumin and creatinine: a population-based study. JAMA Neurol. 2014;71(9):1134&#x2013;1142. doi: 10.1001/jamaneurol.2014.1129.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2014.1129</ArticleId><ArticleId IdType="pubmed">25048026</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun C, Fournier CN, Ye S, Zhang N, Ma Y, Fan D. Chinese validation of the rasch-built overall amyotrophic lateral sclerosis disability scale. Eur J Neurol. 2021;28(6):1876&#x2013;1883. doi: 10.1111/ene.14811.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.14811</ArticleId><ArticleId IdType="pubmed">33686758</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>